On September 4, 2026, Novartis announced that pelacarsen, its experimental cardiovascular drug, had failed to meet its primary endpoint in the Phase 3 Lp(a)HORIZON trial. The drug did not reduce the risk of major adverse cardiovascular events—including deaths, heart attacks, and strokes—compared to placebo, despite successfully lowering lipoprotein(a) levels by up to 80% in patients. Novartis shares dropped 4.4% to $153.00 in after-hours trading following the announcement.
The trial enrolled over 8,000 patients with established cardiovascular disease and elevated Lp(a) levels (≥70 mg/dL), making it the first prospective outcomes study for any Lp(a)-lowering therapy. The primary endpoint measured time to first MACE (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, or urgent coronary revascularization requiring hospitalization). While pelacarsen achieved its biochemical effect, this did not translate into clinical benefit.
The fundamental disconnect lies in the relationship between biomarker modification and actual patient outcomes. Pelacarsen, an antisense oligonucleotide developed by Ionis Pharmaceuticals and licensed to Novartis in 2019, was designed to inhibit apolipoprotein(a) production in the liver. Phase 2 trials showed it could reduce Lp(a) levels by up to 80%, and the Phase 3 trial confirmed this biochemical success.
However, patients in the trial were already receiving optimal, guideline-directed cardiovascular care, including statins and other standard therapies. This created a high bar for demonstrating incremental benefit. UBS analysts had estimated pelacarsen would need to achieve approximately 12% relative risk reduction for statistical significance, while clinicians wanted to see 15% or more for clear clinical meaningfulness. The drug failed to reach either threshold.
The failure challenges fundamental assumptions about Lp(a) as a therapeutic target. While genetic studies strongly suggested Lp(a) was causally related to cardiovascular risk, this trial shows that pharmacologic lowering in adults with established disease may not replicate the genetic effect. It raises questions about whether Lp(a) lowering needs to occur earlier in the disease process (primary prevention) rather than in patients who already have cardiovascular disease.
The pelacarsen failure represents a multibillion-dollar revenue shortfall for Novartis's cardiovascular portfolio, which was already facing substantial patent cliff pressures. The drug was positioned as one of four upcoming launches expected to achieve "multibillion-dollar peak sales," specifically intended to establish "post-Entresto cardiovascular leadership" as Novartis faced generic competition for its $7.8 billion heart failure drug.
Novartis had projected +5-6% constant currency sales CAGR from 2025-2030, with pelacarsen as a key contributor. Management had already characterized 2026 as the company's "largest patent expiry period in its history" with expected low single-digit growth. The loss reduces the number of high-value cardiovascular assets available to offset $10+ billion in combined Entresto and Xolair sales at risk.
Despite the setback, Novartis spent approximately $11.2 billion on R&D in 2025 (up from $10.0 billion in 2024), demonstrating continued commitment to innovation. However, the failure will trigger strategic R&D reallocation. Resources will shift toward higher-probability assets in oncology, immunology, and neuroscience, particularly toward de-risked, late-stage assets with clearer regulatory pathways and commercial potential.
Interestingly, Royalty Pharma—which held 25% of Ionis's pelacarsen royalty payments through a January 2023 funding agreement—emerges relatively unscathed. The company's $500 million investment was structured protectively, with $350 million allocated to stable SPINRAZA royalties and only $150 million to the high-risk pelacarsen upside.
Royalty Pharma expects to recoup its total investment and earn a modest positive return despite the pelacarsen failure. The company's royalty interest in SPINRAZA will revert to Ionis after royalty payments reach $550 million, representing a 1.1x return on the total amount funded. Royalty Pharma reiterated its 2030 Portfolio Receipts target of $4.7 billion or more, and its stock showed minimal volatility following the announcement.
The financial relationship between Novartis and Royalty Pharma was indirect—Novartis paid royalties to Ionis, which then shared 25% with Royalty Pharma. Since pelacarsen will not be commercialized, this entire royalty chain is eliminated. However, the structured deal approach demonstrates Royalty Pharma's sophisticated risk management capabilities.
The pelacarsen failure will force Novartis to make difficult strategic decisions about its cardiovascular pipeline. The company will likely maintain a streamlined cardiovascular presence focused on rare diseases and established mechanisms while significantly shifting resources toward higher-growth therapeutic areas.
Novartis's remaining cardiovascular assets include Leqvio (inclisiran) for LDL cholesterol lowering, Fabhalta (iptacopan) for PNH and IgA nephropathy, Vanrafia (atrasentan) for IgA nephropathy, and Abelacimab, a Factor XI anticoagulant in Phase 3. These programs will receive continued support, but investment in novel cardiovascular mechanisms without strong human validation will decrease.
The company faces critical trade-offs between maintaining cardiovascular capabilities versus shifting resources to oncology, immunology, and neuroscience. Novartis has identified eight de-risked, in-market assets with $3-10 billion peak sales potential: Kisqali, Cosentyx, Kesimpta, Pluvicto, Scemblix, Leqvio, Fabhalta, and Rhapsido. The pelacarsen failure increases pressure on these remaining assets to deliver.
The pelacarsen experience will fundamentally transform Novartis's risk assessment methodology for cardiovascular drug development. The company will place greater emphasis on "causal biology" rather than associative biomarkers, increased requirement for Mendelian randomization studies and genetic evidence supporting target causality, and deeper analysis of disease biology drivers before major investment decisions.
Clinical trial design will also evolve. Novartis will likely implement more rigorous validation of clinical endpoints and their relationship to biomarker changes, better stratification of patient subgroups most likely to benefit from targeted interventions, and careful assessment of standard of care evolution and its impact on demonstrating incremental benefit.
The company has been developing AI and machine learning models for predicting drug development success using two decades of clinical trial data. These predictive models can augment human judgment to make more informed risk-management decisions. The pelacarsen failure will likely accelerate the adoption of these data-driven approaches.
Novartis's ability to maintain its +5-6% mid-term sales growth guidance will depend heavily on successful execution in oncology, immunology, and neuroscience. The company expects 15+ potentially submission-enabling readouts over the next two years, with a pipeline featuring 30+ potential high-value medicines across four core therapeutic areas.
The pelacarsen failure serves as a reminder of the inherent risks in pharmaceutical R&D and the importance of portfolio diversification. However, Novartis's response will likely be measured and strategic, maintaining overall R&D investment while reallocating resources to areas with higher probability of success and commercial impact.
For patients with elevated Lp(a) levels, the setback is disappointing. Approximately one in five people worldwide have elevated Lp(a), an inherited cardiovascular risk factor with no approved targeted treatment. While pelacarsen failed to demonstrate benefit, the trial provides important evidence that advances scientific understanding of the relationship between Lp(a) lowering and cardiovascular outcomes.
The broader Lp(a)-lowering drug class, including competing programs from Amgen (olpasiran) and Eli Lilly (lepodisiran), may face increased regulatory scrutiny as a result. But for now, Novartis must focus on executing its pivot toward therapeutic areas where it has clearer competitive advantages and stronger growth trajectories.
